279 related articles for article (PubMed ID: 34433332)
1. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison.
Lei X; Zhang J; Xu Q; Li J; Qian Y; Zhang J; Liu L; Zhong W; Wang Y; Han X; Tang J; Zeng M; Mao Y
J Int Med Res; 2021 Aug; 49(8):3000605211039810. PubMed ID: 34433332
[No Abstract] [Full Text] [Related]
2. An analysis of silybin meglumine tablets in the treatment of drug-induced liver injury as assessed for causality with the updated Roussel Uclaf Causality Assessment Method using a nationwide database.
Zhang B; Jiang G; Wang L; Li X; Zhao C; Tan Q; Kang W; Feng Y; Han X; Raza HK; Mao Y
Br J Clin Pharmacol; 2023 Apr; 89(4):1329-1337. PubMed ID: 36278948
[TBL] [Abstract][Full Text] [Related]
3. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.
Teschke R; Méndez-Sánchez N; Eickhoff A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563242
[TBL] [Abstract][Full Text] [Related]
4. Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.
Teschke R; Danan G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446036
[TBL] [Abstract][Full Text] [Related]
5. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM).
Teschke R; Danan G
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33800917
[TBL] [Abstract][Full Text] [Related]
6. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
Teschke R; Schulze J; Eickhoff A; Danan G
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
[TBL] [Abstract][Full Text] [Related]
7. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.
Teschke R
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1169-1187. PubMed ID: 30354694
[TBL] [Abstract][Full Text] [Related]
8. Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score.
Danjuma MI; Almasri H; Alshokri S; Khir FK; Elmalik A; Battikh NG; Abdallah IMH; Elshafei M; Fatima H; Mohamed MFH; Maghoub Y; Hussain T; Kamal I; Anwer Z; Bidmos MA; Elzouki AN
BMC Geriatr; 2020 Sep; 20(1):346. PubMed ID: 32928134
[TBL] [Abstract][Full Text] [Related]
9. Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method.
Ye L; Feng Z; Huang L; Guo C; Wu X; He L; Tan W; Wang Y; Wu X; Hu B; Li T; Yang G; Chengxian G; He Q
Front Pharmacol; 2021; 12():790108. PubMed ID: 34987403
[No Abstract] [Full Text] [Related]
10. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
[TBL] [Abstract][Full Text] [Related]
11. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future.
Danan G; Teschke R
Front Pharmacol; 2019; 10():853. PubMed ID: 31417407
[TBL] [Abstract][Full Text] [Related]
12. Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment.
Mullins C; Beaulac K; Sylvia L
Ann Pharmacother; 2020 Jun; 54(6):526-532. PubMed ID: 31786964
[No Abstract] [Full Text] [Related]
13. Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study.
Rodríguez A; García-García I; Martínez de Soto L; Gómez López De Las Huertas A; Borobia AM; González-Torbay A; Akatbach-Bousaid I; González-Muñoz M; Ramírez E
Front Pharmacol; 2022; 13():819589. PubMed ID: 35370653
[No Abstract] [Full Text] [Related]
14. Outcomes and Predictors of Mortality in Patients With Drug-Induced Liver Injury at a Tertiary Hospital in South India: A Single-Centre Experience.
Sunil Kumar N; Remalayam B; Thomas V; Ramachandran TM; Sunil Kumar K
J Clin Exp Hepatol; 2021; 11(2):163-170. PubMed ID: 33746440
[TBL] [Abstract][Full Text] [Related]
15. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?
Danan G; Teschke R
Drug Saf; 2018 Aug; 41(8):735-743. PubMed ID: 29502198
[TBL] [Abstract][Full Text] [Related]
16. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.
Teschke R; Danan G
Medicines (Basel); 2020 Sep; 7(10):. PubMed ID: 33003400
[No Abstract] [Full Text] [Related]
17. Bicyclol for the treatment of drug-induced liver injury: a propensity score matching analysis using a nationwide inpatient database.
Wang Y; Lai R; Zong P; Xu Q; Shang J; Zhang X; Zhong W; Tang J; Han X; Chen C; Mao Y
J Int Med Res; 2021 Apr; 49(4):3000605211005945. PubMed ID: 33853430
[TBL] [Abstract][Full Text] [Related]
18. A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale.
Hanatani T; Sai K; Tohkin M; Segawa K; Kimura M; Hori K; Kawakami J; Saito Y
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):984-8. PubMed ID: 24596340
[TBL] [Abstract][Full Text] [Related]
19. Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): an overview.
Teschke R; Eickhoff A; Schulze J; Danan G
Transl Gastroenterol Hepatol; 2021; 6():51. PubMed ID: 34423172
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: A phase II trial.
Wang Y; Wang Z; Gao M; Zhong H; Chen C; Yao Y; Zhang Z; Zhang X; Li F; Zhang J; Gu HM; Chen Y; Tang J; Zhong W; Zeng M; Mao Y
Liver Int; 2019 Nov; 39(11):2102-2111. PubMed ID: 31379118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
